PROTRIPTYLINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Protriptyline Hydrochloride, and what generic alternatives are available?

Protriptyline Hydrochloride is a drug marketed by Epic Pharma Llc, Hikma, and Sigmapharm Labs Llc. and is included in three NDAs.

The generic ingredient in PROTRIPTYLINE HYDROCHLORIDE is protriptyline hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the protriptyline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Protriptyline Hydrochloride

A generic version of PROTRIPTYLINE HYDROCHLORIDE was approved as protriptyline hydrochloride by SIGMAPHARM LABS LLC on May 3^rd, 2010.

Summary for PROTRIPTYLINE HYDROCHLORIDE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	878
DailyMed Link:	PROTRIPTYLINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for PROTRIPTYLINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4
Roxane Laboratories	N/A

See all PROTRIPTYLINE HYDROCHLORIDE clinical trials

Pharmacology for PROTRIPTYLINE HYDROCHLORIDE

Drug Class

Tricyclic Antidepressant

Medical Subject Heading (MeSH) Categories for PROTRIPTYLINE HYDROCHLORIDE

Adrenergic Uptake Inhibitors

Antidepressive Agents, Tricyclic

Anatomical Therapeutic Chemical (ATC) Classes for PROTRIPTYLINE HYDROCHLORIDE

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for PROTRIPTYLINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	PROTRIPTYLINE HYDROCHLORIDE	protriptyline hydrochloride	TABLET;ORAL	202220-001	Nov 19, 2012	AB	RX	No	No
Hikma	PROTRIPTYLINE HYDROCHLORIDE	protriptyline hydrochloride	TABLET;ORAL	078913-002	Sep 16, 2008		DISCN	No	No
Epic Pharma Llc	PROTRIPTYLINE HYDROCHLORIDE	protriptyline hydrochloride	TABLET;ORAL	202220-002	Nov 19, 2012	AB	RX	No	Yes

Market Dynamics and Financial Trajectory for Protriptyline Hydrochloride

Last updated: February 15, 2026

Protriptyline hydrochloride is a tricyclic antidepressant (TCA) primarily used for depression, attention deficit hyperactivity disorder (ADHD), and certain sleep disorders. Its market dynamics are influenced by regulatory status, competition, patent expiration, and clinical positioning. Financial trajectories depend on sales volume, pricing strategies, manufacturing costs, and regulatory filings.

---

Regulatory Status and Patent Landscape

Protriptyline hydrochloride received FDA approval in the 1960s. It is an off-patent generic medication for depression and certain off-label indications. As of 2023, no major patents protect new formulations or indications. Patent expiration in the U.S. occurred around 2000-2001 for primary formulations. The absence of patent restrictions limits exclusivity, impacting pricing and revenue opportunity.

Market Size and Segmentation

The global antidepressant market was valued at approximately USD 16 billion in 2022, with TCAs accounting for roughly 2% of that market (USD 320 million). Protriptyline’s share is minimal given:

• Preference for SSRIs and SNRIs due to better safety profiles.
• Limited use for off-label indications.
• Availability of newer therapies.

Within the TCA segment, protriptyline is a niche product, primarily used in specific cases where other TCAs are contraindicated or ineffective. The off-label use for ADHD and sleep disorders marginally expands its application but lacks significant commercial momentum.

Competitive Landscape

Main competitors include amitriptyline, nortriptyline, and imipramine. These drugs dominate the TCA market with established prescribing patterns. Newer antidepressants have displaced TCAs in primary care, although TCAs retain specialized roles.

Protriptyline’s competitive position is weak:

• Lower side-effect profile than older TCAs.
• Limited evidence base compared to newer agents.
• Established formulations in mature markets.

The competitive landscape discourages substantial investment in R&D for protriptyline, focusing instead on generics and niche indications.

Pricing and Reimbursement

As a generic, protriptyline hydrochloride commands low per-unit prices, often under USD 0.10 per tablet. Margins are thin; payers favor less toxic and more tolerable newer drugs. Insurance reimbursement rates are minimal, particularly outside specialized clinics.

Manufacturing and Supply Chain

Protriptyline hydrochloride is coproduced by generic manufacturers, mainly in India and China. Oversupply can depress prices further, while supply disruptions—though rare—could temporarily influence market availability.

---

Financial Trajectory and Investment Outlook

The revenue potential of protriptyline hydrochloride remains limited:

• Currently, annual sales likely under USD 20 million globally.
• Growth prospects are stagnant due to market saturation and competition.
• No significant pipeline innovations or formulations are publicly known.

Investors or pharmaceutical companies aiming to capitalize on this drug should note:

• Limited upside in traditional markets.
• Possible niche or off-label expansion unlikely to generate substantial revenue.
• Investment is better directed toward innovating or repositioning newer agents with higher margins and growth potential.

Market Trends and Future Outlook

Key trends impacting protriptyline include:

• Shift toward SNRI and SSRI agents.
• Increasing regulatory and safety concerns about TCAs.
• Growing interest in personalized medicine, potentially limiting off-label use.

Long-term growth prospects are minimal absent reformulation, new indications, or a strategic repositioning.

---

Key Takeaways

• Protriptyline hydrochloride operates as a low-margin generic with minimal market expansion potential.
• Dominated by older, established global generic manufacturers.
• No patents protect new uses, curbing exclusivity-driven revenue.
• The segment is declining in favor of modern antidepressants with better safety profiles.
• Financial opportunities are limited to niche markets or repositioning strategies.

---

FAQs

1. Can protriptyline hydrochloride gain regulatory approval for new indications?
It is unlikely due to limited clinical evidence and its current generic status. Regulatory efforts are more feasible for developing novel formulations or combination therapies.

2. Is there potential for market growth in developing countries?
Yes, in regions with limited access to newer antidepressants, protriptyline could retain niche demand. However, pricing pressures and local competition may limit profitability.

3. Are there any ongoing pipeline developments for protriptyline?
No publicly available development or reformulation pipelines are underway as of 2023.

4. How does safety profile affect market position?
Protriptyline’s safety profile is comparable or inferior to newer antidepressants, reducing its attractiveness for prescribers and limiting market share.

5. What strategic approaches could revitalize protriptyline’s market?
Repositioning as a specialized or investigational treatment for specific neurological conditions or developing generic combination products could create niche opportunities.

---

Sources:

1. GlobalData, "Antidepressant Market Report," 2022.
2. U.S. FDA, “Approved Drugs Database,” 2023.
3. IQVIA, "Pharmaceutical Market Data," 2022.
4. Statista, “Antidepressant Market Size,” 2023.
5. MarketWatch, “Generic Drug Market Trends,” 2023.